OS Therapies Incorporated (NYSE:OSTX) shares are up during Tuesday’s premarket session as the company recently announced that its Phase 2b trial of OST-HER2 achieved statistically significant overall survival results at the 2.5-year mark.
OST-HER2 Shows Statistically Significant Survival Benefit
Something went wrong.
The trial results indicate a survival rate of 75% for patients treated with OST-HER2 compared to 47% in the historical control group, with a p-value of 0.003, in pulmonary metastatic osteosarcoma patients, a primary bone cancer metastasizes to the lungs
The topline data shows improving OST-HER2 survival benefit when compared with the 2-year data (2-year overall survival was 75% vs. 60%, p = 0.034).
